Truist Financial reissued their buy rating on shares of Scholar Rock (NASDAQ:SRRK – Free Report) in a research report released on Monday, Benzinga reports. Truist Financial currently has a $20.00 price target on the stock.
Other equities research analysts also recently issued research reports about the company. HC Wainwright reissued a buy rating and set a $30.00 price objective on shares of Scholar Rock in a report on Tuesday, March 19th. Wedbush reissued an outperform rating and set a $23.00 price objective on shares of Scholar Rock in a report on Tuesday, January 23rd. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Scholar Rock has an average rating of Buy and a consensus price target of $23.80.
Get Our Latest Research Report on Scholar Rock
Scholar Rock Trading Down 2.3 %
NASDAQ SRRK opened at $16.01 on Monday. The company has a quick ratio of 8.80, a current ratio of 8.80 and a debt-to-equity ratio of 0.22. Scholar Rock has a twelve month low of $5.56 and a twelve month high of $21.17. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -8.05 and a beta of 0.89. The business’s fifty day moving average is $15.57 and its 200 day moving average is $13.25.
Insiders Place Their Bets
In other Scholar Rock news, insider Mo Qatanani sold 2,512 shares of Scholar Rock stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.74, for a total transaction of $39,538.88. Following the transaction, the insider now directly owns 147,019 shares of the company’s stock, valued at approximately $2,314,079.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, General Counsel Junlin Ho sold 3,489 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.74, for a total value of $54,916.86. Following the transaction, the general counsel now directly owns 208,771 shares of the company’s stock, valued at approximately $3,286,055.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mo Qatanani sold 2,512 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.74, for a total value of $39,538.88. Following the completion of the transaction, the insider now directly owns 147,019 shares in the company, valued at $2,314,079.06. The disclosure for this sale can be found here. In the last three months, insiders have sold 46,303 shares of company stock valued at $769,490. 26.20% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in SRRK. Swiss National Bank increased its position in Scholar Rock by 9.3% in the 1st quarter. Swiss National Bank now owns 54,000 shares of the company’s stock valued at $696,000 after buying an additional 4,600 shares in the last quarter. MetLife Investment Management LLC increased its holdings in Scholar Rock by 54.1% during the 1st quarter. MetLife Investment Management LLC now owns 16,604 shares of the company’s stock worth $214,000 after purchasing an additional 5,832 shares in the last quarter. Rhumbline Advisers increased its holdings in Scholar Rock by 7.0% during the 1st quarter. Rhumbline Advisers now owns 29,405 shares of the company’s stock worth $379,000 after purchasing an additional 1,918 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Scholar Rock by 23.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 178,984 shares of the company’s stock worth $2,307,000 after purchasing an additional 34,416 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Scholar Rock by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 1,490,795 shares of the company’s stock worth $19,217,000 after purchasing an additional 38,917 shares in the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Featured Stories
Receive News & Ratings for Scholar Rock Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Scholar Rock and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
/cloudfront-us-east-1.images.arcpublishing.com/pmn/X6WXZ45CTJGKRMHHJYBUZ2TAKA.jpg)
